CRISPR takes a bold leap toward silencing Down syndrome's extra chromosome

Key Points:

• Scientists have developed a gene therapy approach using a modified CRISPR/Cas9 technique to insert the XIST gene into the extra chromosome 21, aiming to silence its activity in Down syndrome (DS) cells.
• This method leverages the natural process where the XIST gene inactivates one of the two X chromosomes in females, applying it to silence the extra chromosome responsible for DS.
• Laboratory tests on human stem cells showed successful integration of the XIST gene into the extra chromosome 21 with an efficiency of 20 to 40%, marking a significant proof-of-concept.
• While the technique did not silence the extra chromosome in most cells, it represents a crucial step toward potential gene therapies that target entire chromosomes without widespread cellular damage.
• Further research, including animal studies, is needed to confirm safety, rule out off-target effects, and demonstrate therapeutic benefits before this approach can be developed into a treatment for DS.